Abstract
Introduction

39
Hepatitis C caused by hepatitis C virus (HCV) has been called silent epidemic. The majority of 40 infections are asymptomatic, but in 20% of cases the virus persist, leading to chronic hepatitis (1) 41 causing liver fibrosis and cirrhosis, which is often a prelude to hepatocellular carcinoma (2).
42
Liver transplantation is often necessary in a portion of HCV infected patients (3). Tremendous promising approach against HCV drug resistance development and infection relapse (9).
57
Moreover, prevention of donor liver re-infection by inhibiting viral entry into hepatocytes might 58 be achieved using DAAs targeting entry.
59
Hepatitis C virus is an enveloped positive-stranded RNA virus encoding a polyprotein, co-and 
Materials and Methods
91
Chemicals and antibodies
92
DMEM, goat and fetal bovine sera were purchased from Invitrogen (Carlsbad, CA). 4',6-93 diamidino-2-phenylindole (DAPI) was from Molecular Probes (Invitrogen). EGCG used as a 94 control was from Calbiochem (Merck Chemicals, Darmstadt, Germany). Theaflavin 3,3'-95 digallate used to compare with our extracted theaflavin, TF3, was from PhytoLab (Germany). was measured by luciferase activity quantification using Luciferase Assay Kit (Promega) and a
163
Berthold luminometer. were generally used in micrograms in the experiments. (Fig 2A) . The half effective concentration (EC 50 ) was calculated for each molecule to be 17.89, 4.08, and 2.02 µM for TF1, TF2 and TF3, respectively. TF3 is the most active. We then tested 216 the effect of theaflavins on cell viability by treating Huh-7 with a range of theaflavin 217 concentrations that were used in inhibition experiments, 0 to 250 µg/ml, with three different 218 exposure times, 24, 48 and 72 h (Fig 2B-D) . Theaflavins did not decrease cell viability up to 9 219 100 µg/ml after short (24 h) to long (72 h) exposure times, a concentration much higher than the 220 active antiviral concentrations. 
Theaflavins inhibit HCV entry and not replication 233
The HCV infection cycle is a multistep process that involves entry of the virus into the cell,
234
replication of the genomic RNA and assembly/release of viral particles. To determine at which 235 step the different theaflavins exert their action, a time of addition experiment was performed.
236
The compounds were added before, during or after inoculation of HCV to Huh-7 cells. EGCG,
237
an inhibitor of HCV entry, and Boceprevir, a HCV NS3 protease inhibitor, were used as controls.
238
The result clearly demonstrates a significant inhibition of HCV only in the presence of 239 theaflavins added during inoculation, like EGCG (Fig 3A) . There was no inhibition when 
247
Theaflavins, at 25 µg/ml were either added for 2 h to the cells before infection (step 1), or during 248 inoculation (step 2), or during the 28 h after inoculation (step 3), or during the 3 steps (step 1+2+3). by Boceprevir (Fig 4) . Taken together, our results show the TF1, TF2 and TF3 are inhibitors of
273
HCV entry and not replication. Theaflavins act directly on the viral particle
282
Theaflavins can inhibit HCV entry by acting either directly on the viral particle or on cellular
283
factors. This second hypothesis seems unlikely because no effect of theaflavins on HCV
284
infection was observed when cells were pre-treated with the molecules before infection (Fig 3A) .
285
To determine if theaflavins act directly on the viral particle, HCV viral stocks were incubated 
316
Inoculum was replaced by medium containing mAb 3/11 neutralizing antibody to prevent extracellular 317 propagation. Theaflavins at 25 µg/ml or EGCG at 50 µM were added in the medium after inoculation.
318
Cells were fixed 72 h after infection and subjected to immunofluorescence detection of E1 HCV envelope Sofosbuvir and Daclatasvir in an additive manner (Fig 7) demonstrating that it could be use in 333 combination with DAA used in hepatitis C therapy. dose-dependent inhibition of HCV by theaflavins (Fig 3B-D) . This represents an important hit 365 for further drug development.
366
In recent times, a number of promising natural products with anti-HCV activities have been 367 discovered (37-39). viruses that could be more exploited in the context of antiviral therapy.
389
A future prospect of our study may be to determine the bioavailability of theaflavins in human 
400
In conclusion, the present study identified theaflavins as new entry inhibitors of HCV infection.
401
Their pan-genotypic action and ability to inhibit cell-to-cell spread are major advantages for 
